Shunchang C. Jiao

No. 28 Fuxing Road
Haidian, 100853, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 150 publications

Multi-omics analysis reveals the role of tumor-infiltrating CD4+CCR7+ T cells in EGFR antibody resistance and prognosis of hepatocellular carcinoma.

Multi-omics analysis reveals the role of tumor-infiltrating CD4+CCR7+ T cells in EGFR antibody resistance and prognosis of hepatocellular carcinoma.

Journal: BMC cancer

Published: July 22, 2025

NQO1/p65/CXCL12 Axis-Recruited Tregs Mediate Resistance to Anti-PD-1 Plus Lenvatinib Therapy in PIVKA-II-Positive Hepatocellular Carcinoma.

NQO1/p65/CXCL12 Axis-Recruited Tregs Mediate Resistance to Anti-PD-1 Plus Lenvatinib Therapy in PIVKA-II-Positive Hepatocellular Carcinoma.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: June 18, 2025

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

Journal: Hepatobiliary surgery and nutrition

Published: February 28, 2025

Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).

Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).

Journal: Bioscience trends

Published: December 25, 2024

Multi-omics analyses reveal interactions between GREM1+ fibroblasts and SPP1+ macrophages in gastric cancer.

Multi-omics analyses reveal interactions between GREM1+ fibroblasts and SPP1+ macrophages in gastric cancer.

Journal: NPJ precision oncology

Published: December 25, 2024

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: December 16, 2024

Immunological characteristics of peripheral T cells as prognostic markers for Camrelizumab and Apatinib combination therapy in advanced squamous non-small-cell lung cancer.

Immunological characteristics of peripheral T cells as prognostic markers for Camrelizumab and Apatinib combination therapy in advanced squamous non-small-cell lung cancer.

Journal: Molecular immunology

Published: October 01, 2024

Short‑term efficacy assessment of brigatinib for the treatment of neurofibromatosis type 2: A retrospective study.

Short‑term efficacy assessment of brigatinib for the treatment of neurofibromatosis type 2: A retrospective study.

Journal: Oncology letters

Published: August 29, 2024

Development and validation of a novel nerve-related prognostic model for gastric cancer based on bulk and single-cell RNA sequencing data.

Development and validation of a novel nerve-related prognostic model for gastric cancer based on bulk and single-cell RNA sequencing data.

Journal: BMC cancer

Published: August 29, 2024

CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival.

CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival.

Journal: Oncoimmunology

Published: May 30, 2024

Single-cell RNA sequencing reveals intratumoral heterogeneity and multicellular community in primary hepatocellular carcinoma underlying microvascular invasion.

Single-cell RNA sequencing reveals intratumoral heterogeneity and multicellular community in primary hepatocellular carcinoma underlying microvascular invasion.

Journal: Heliyon

Published: April 18, 2024

Tumor-derived DEFB1 induces immune tolerance by inhibiting maturation of dendritic cell and impairing CD8+ T cell function in esophageal squamous cell carcinoma.

Tumor-derived DEFB1 induces immune tolerance by inhibiting maturation of dendritic cell and impairing CD8+ T cell function in esophageal squamous cell carcinoma.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: March 17, 2024

Showing 1-12 of 150

Last Updated: 09/26/2026